Multi-Phase Based Signature and Cancer Management: An Insight in Embryo, Brain Tumor, Leukemia, and Von Hippel Lindau Syndrome

Abstract

It has initiated the multi-phase (MPh) phenomen through the cell cycle machinery, and is an icon related to the novel cell cycle M.Ph, characteristics in variety of neoplastic disorders, including cancer. Cell cycle governs the whole cell based machinery, initiation, progression, and therapeutic platforms in the neoplastic disorders. Differentiation between benign and malignant cells relies on the functional data within the cell cycle domain. Cancer initiation, progressive manner and therapeutic sphere are also dictated by cell cycle. Proliferation and growth play key role in initiation and develoment of tumors, including benign and malignant cells. The cell cycle’s checkpoints are restrictively under the cell cycle control. As the matter of fact, it was trusted that there is no return through the routine cell cycling and it was characterized as an everlasting forward cycling manner. But this fact has been revolutionized through the presence of Mosaic multi-phase (M.Ph) based at single cell level. The programmed checkpoints control the transition of phases through the related barriers. Therefore, balancing the carcinogenic processes is capable to control progression, facilitate and guarantee the most effective and personalized/ target based therapy The multi-phase based strategy has been also performed in the circulating embryonic, fetal chorionic sample (CVS), chronic myeloblastic leukemia and Von Hippel lindau (VHL) syndrome, Conclusively, early predictive/prognostic value of MPh provides a reliable, personalized diagnostic and diverse target-based therapeutic platforms in different medical complications.